Pharsight

Astellas patents expiration

1. Cresemba patents expiration

CRESEMBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(2 years from now)

US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(3 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 6, 2022
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
ODE* (ODE*) Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 2026-03-06

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

2. Lexiscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(1 year, 5 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(3 years from now)

Drugs and Companies using REGADENOSON ingredient

Market Authorisation Date: 10 April, 2008

Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage

LEXISCAN family patents

Family Patents

3. Veozah patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871761 ASTELLAS NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Apr, 2031

(7 years from now)

US9422299 ASTELLAS Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10836768 ASTELLAS N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(10 years from now)

US9987274 ASTELLAS N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 12, 2028

Drugs and Companies using FEZOLINETANT ingredient

NCE-1 date: 2027-05-13

Market Authorisation Date: 12 May, 2023

Treatment: Treatment of moderate to severe vasomotor symptoms due with menopause; Treatment of moderate to severe vasometer symptoms due to menopause

Dosage: TABLET;ORAL

More Information on Dosage

VEOZAH family patents

Family Patents

4. Vesicare Ls patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918970 ASTELLAS Pharmaceutical composition comprising solifenacin
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 26, 2023
Pediatric Exclusivity (PED) Nov 26, 2023

Drugs and Companies using SOLIFENACIN SUCCINATE ingredient

Market Authorisation Date: 26 May, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of VESICARE LS before it's drug patent expiration?
More Information on Dosage

VESICARE LS family patents

Family Patents

5. Xospata patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound
Jul, 2030

(6 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Chemical Entity Exclusivity (NCE) Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 2022-11-28

Market Authorisation Date: 28 November, 2018

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET;ORAL

How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage

XOSPATA family patents

Family Patents

6. Xtandi patents expiration

XTANDI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
May, 2026

(2 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 16, 2022

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 04 August, 2020

Treatment: Treatment of patients with castration-resistant prostate cancer (crpc); The treatment of patients with metastatic castration-resistant prostate cancer (crpc).; The treatment of patients with metastati...

Dosage: TABLET;ORAL

How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage

XTANDI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic